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Cancer is a leading cause of death in children. In the past decades, there has been a marked increase in overall
survival of children with cancer. However, children whose treatment includes hematopoietic stem cell
transplantation still represent a subpopulation with a higher risk of mortality. These improvements in mortality are
accompanied by an increase in complications, such as respiratory and cardiovascular insufficiencies as well as
neurological problems that may require an admission to the pediatric intensive care unit where most supportive
therapies can be provided. It has been shown that ventilatory and cardiovascular support along with renal
replacement therapy can benefit pediatric hemato-oncology patients if promptly established. Even if admissions of
these patients are not considered futile anymore, they still raise sensitive questions, including ethical issues. To
support the discussion and potentially facilitate the decision-making process, we propose an algorithm that takes
into account the reason for admission (surgical versus medical) and the hemato-oncological prognosis. The
algorithm then leads to different types of admission: full-support admission, “pediatric intensive care unit trial”
admission, intensive care with adapted level of support, and palliative intensive care. Throughout the process,
maintaining a dialogue between the treating physicians, the paramedical staff, the child, and his parents is of
paramount importance to optimize the care of these children with complex disease and evolving medical status.
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Children represent only 1% of all patients with malig-
nant neoplasms [1]. Nevertheless, in developed coun-
tries, cancer is the second most common cause of death
in children older than age 1 year, after trauma [2].
Tumor-related issues as well as the intensity of therapy
itself can lead to severe and life-threatening complica-
tions that may require admission to a pediatric intensive
care unit (PICU).
Historically, these children have been regarded as poor
candidates for intensive care. Given their grim prognosis
[3,4], their admission to the PICU raised difficult issues,
ethically and operationally. During the past decades, there* Correspondence: demaret.pierre@gmail.com
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in any medium, provided the original work is phas been a marked improvement in the prognosis of chil-
dren with cancer (5-year survival increasing from approxi-
mately 40% in the 1970s to approximately 80% in the
2000s [1,5]) as well as their intensive care outcome [6-8].
The objectives of this review are to characterize the
specificities of the critically ill child with cancer, to re-
view the organ support strategies that can be offered,
and to assist pediatricians, hemato-oncologists, and
pediatric intensivists in transitioning these patients to
the PICU. Given their specific challenges, children who
undergo hematopoietic stem cell transplantation (HSCT)
will be discussed separately.The pediatric hemato-oncologic patient (non-HSCT)
admitted to the PICU
Epidemiology
One of every three or four children with cancer is admit-
ted to the PICU at least once during the course of theirs an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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10% of all PICU admissions [11-15].
Reasons for admission
The main reasons for admission to the PICU are listed
in Table 1. Sepsis and respiratory failure are responsible
for approximately two-thirds of nonsurgical PICU
admissions [12,15-17].
Mortality and prognostic factors
Mortality is primarily influenced by the type of admission
(surgical vs. nonsurgical). Children admitted postopera-
tively have a very low mortality rate (0-4%) [10,11,17]. Be-
cause their prognosis does not differ from that of the
general population of intensive care, they are excluded
from the majority of the populations studied.
Mortality of medical cases is higher. The large multi-
center study by Dalton et al. (n = 802) demonstrated a
13.3% mortality rate for children with cancer admitted
for nonsurgical causes (30/226) [11]. Smaller single-
center pediatric series, considering patients admitted to
the PICU in the 2000s, have reported a mortality rate
ranging from 15% to 20% [15,24]. These results, al-
though higher than the mortality rate of the general
PICU population, are encouraging compared with the
50% mortality rate reported in the 1980s [16].
As with the general PICU population, the degree of
multiorgan failure is systematically related to prognosis;
mortality exceeds 70% if three or more organs are
involved [10,17,20,24]. The use of mechanical ventilation
and/or inotropic support, related to respiratory and/or







(% of PICU admission)
72% [11] 4–16% [18,19]
Medical reasona
Respiratory failure 26–58% [10,15,17,20] 33–88% [19,21-23]
Airway compressionb
(% of respiratory failure)
0–48% [10,17,20] 0% [19,21-23]
Lung disease
(% of respiratory failure)
52–100%c [10,15,17,20] 100%d [19,21-23]
Severe sepsis/septic
shock
8–36% [10,15,17,20,24] 21–36% [18,19,21,23]
Neurological problem 10–31% [10,15,17,20,24] 3–20% [18,19,21,25]
Renal dysfunction 5–15% [10,15,20] 5–8% [21,22,25]
Tumor lysis syndrome 5–8% [10,15]
HSCT=hematopoietic stem cell transplantation.
aPercentages indicate the proportion of medical admissions only; bairway
compression by a tumor or by a mediastinal mass; cmainly due to infection;
dpossible etiologies are infectious pneumonia, idiopathic pneumonia,
bronchiolitis obliterans, pulmonary hemorrhage, pulmonary edema, or GVHD.prognostic factors [10,15,20,24]. Their combination is
associated with a worse prognosis, with mortality reach-
ing 54% to 100% [11,17,20]. It should be noted that chil-
dren ventilated because of airway compression have a
better outcome than those ventilated for lung disease
[10,12,20].
Children admitted to the PICU at the time of diagno-
sis of oncologic disease, before initiation of chemo-
therapy, seem to have a better prognosis than those
admitted later (8% vs. 34%, p = 0.06) [10]. This differ-
ence may be due to differences in the reasons for ad-
mission between these two groups and to the toxicity
of chemotherapy itself.
Some authors also have reported that the type of cancer
influences PICU mortality: children with solid tumors
have a lower mortality rate than those with hematological
malignancies [15,24].
Cancer and respiratory failure in the PICU
Respiratory failure is a major cause of PICU admission
for children with cancer (Table 1). The term “respiratory
failure” is not always clearly defined in the literature
addressing this issue. Acute respiratory distress syn-
drome (ARDS) should be defined according to the
American-European Consensus Conference on ARDS cri-
teria [26]: acute onset, PaO2/FiO2≤ 200 mmHg (regard-
less of positive end-expiratory pressure level), bilateral
infiltrates on chest radiograph, and no evidence of left
atrial hypertension. The acute lung injury (ALI) cri-
teria only differ by the level of PaO2/FiO2, which has
to be ≤ 300 mmHg. The SpO2/FiO2 ratio could be used
in the evaluation of lung disease severity as a surrogate
of the PaO2/FiO2 ratio if an arterial catheter is not
available [27].
Noninvasive ventilation (NIV) is of particular interest
in these patients who are highly susceptible to infections,
because it does not breach the respiratory barrier. The
benefits of NIV for immunocompromised patients have
been documented in both adults [28-31] and children
[32,33].
In a retrospective study of 239 children with cancer
admitted to the PICU for respiratory failure, Pancera
et al. [32] compared children ventilated for at least 24
hours with NIV (nasal biphasic positive airway pressure)
(n = 120) with children ventilated invasively (without
prior NIV or with prior NIV< 24 hours) (n = 119). The
success rate of NIV, defined as the absence of subse-
quent endotracheal intubation, was 74%. In the multi-
variate analysis, predictors of failure of NIV were:
cardiovascular dysfunction, therapeutic intervention
score (TISS) ≥ 40, and presence of a solid tumor. Forty-
six patients (39%) in the invasively ventilated group and
93 (77%) in the NIV group survived to PICU discharge
(p< 0.001). There was a significant difference in the 30-
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(23.3%) and the NIV group (47%; p< 0.0001). It is im-
portant to note that these two groups were derived from
standard practice rather than randomization. Therefore,
the results need to be interpreted with caution.
Two other retrospective studies by Schiller et al. [33]
and Piastra et al. [34] reported data from 14 pediatric
hemato-oncology patients with ALI and 23 pediatric
hemato-oncology patients with ARDS, respectively. All
of these patients received NIV via a full-face mask or a
helmet. Intubation was avoided in 12 of 14 and 13 of 23
patients, respectively. Ten of the 12 intubated patients in
the two studies died eventually compared with 1 of the
25 nonintubated patients.
Whereas a few randomized, controlled trials con-
ducted in the adult population have shown significant
benefits of early implementation of NIV in immunocom-
promised patients [28,30,31], no randomized trials have
been conducted in children with cancer. Studies previ-
ously discussed have a significant potential for selection
biases (the children who received NIV could be less se-
verely ill than those who did not) and for information
biases, inherent to their retrospective nature. However,
considering potential complications related to invasive
ventilation in the hemato-oncology children, and in light
of the benefits of early NIV documented in adults, we
believe it is important to consider a trial of NIV in this
category of patients.
Despite the benefits of NIV, a difficult question
remains: when is the appropriate time to declare NIV a
failure and to initiate invasive ventilation in a pediatric
hemato-oncology patient whose respiratory function is
not improving? Invasive ventilation is documented as a
poor prognostic factor among these children but delay-
ing intubation also could worsen their course. To bal-
ance these effects, close monitoring is essential in all
cases, and a possible switch to invasive ventilation
should be discussed if there is no improvement after the
first 2 hours of ventilation [35]. The criteria identified as
predictive of NIV failure in the general PICU population
are the presence of a second organ failure [36], pH
< 7.25 after 2 hours of treatment [37], the need for a
high level of support (mean pressure> 12 cmH2O or
FiO2> 0.6) [38], and the presence of ARDS [39].Cancer and sepsis
Several factors predispose the child with cancer to sepsis
[40,41]: the chemotherapy regimens responsible for pro-
longed periods of marrow aplasia and disruption of skin
and mucosal barriers, the type of tumor (hematological
malignancies having a greater risk than solid tumors),
the stage of the disease, neutropenia, as well as the pres-
ence of comorbidities and indwelling catheters.Children with cancer in septic shock seem to have a
prognosis similar to that of children without cancer,
according to work by Pound et al. [40]. In this study, 69
pediatric oncology patients admitted to the PICU with a
diagnosis of septic shock (based on the presence of
hypo- or hyperthermia, tachycardia, tachypnea and
hypotension, and evidence of perfusion abnormalities or
organ dysfunction after adequate fluid resuscitation)
were compared with a group of age- and gender-
matched nononcology patients admitted to the PICU
with septic shock during the same time period. No sig-
nificant difference could be demonstrated with respect
to survival status at PICU discharge (16% vs. 12% re-
spectively, p= 0.67) nor at 30 days post-PICU discharge
(23% vs. 15%, p= 0.38). However, there was a significant
difference in mortality at 6 months post-PICU discharge
between the two groups (43% vs. 16%, p= 0.01),
explained by the underlying disease in the oncology
patients, with all deaths being secondary to disease
progression.
Similar results were found by Kutko et al. [42] who
reviewed data from 96 episodes of septic shock (defined
as hypo- or hyperthermia with signs of altered perfusion
and/or hypotension) in 80 PICU patients. Although this
study was not adequately powered for such a compari-
son, there was no difference in mortality rates between
children with cancer (n = 68) and without (n = 28; 12%
vs. 18%, respectively; p= 0.43).
The definitions of sepsis, severe sepsis, and septic
shock in children were established in 2005 by the Inter-
national Pediatric Sepsis Consensus Conference [43]. Sys-
temic inflammatory response syndrome (SIRS) is defined
by the presence of at least two of the followings: hypo-
or hyperthermia, tachycardia or bradycardia, tachypnea
or mechanical ventilation, and elevated or depressed
leukocyte count. Sepsis is defined by SIRS in the pres-
ence of suspected or proven infection. Sepsis is qualified
as severe in case of cardiovascular dysfunction, acute re-
spiratory distress syndrome, or two or more other organ
dysfunctions, whereas septic shock is defined by the asso-
ciation of sepsis and cardiovascular dysfunction. Because
recruitment of patients in both studies evaluating chil-
dren with cancer and septic shock preceded the consen-
sus conference [40,42], the authors based the septic
shock criteria on the Task Force on Hemodynamic Sup-
port from the American College of Critical Care Medi-
cine [44]. These former criteria correspond to the
consensus conference definitions of severe sepsis or sep-
tic shock, allowing comparison with patients admitted to
our PICU with such diagnoses.
The management of children with cancer in septic
shock does not differ substantially from that of other
children and should follow the recommendations of
the Surviving Sepsis Campaign [45]. Broad-spectrum
Table 2 Mortality of children with cancer placed on ECMO
and comparison with patients without cancer (from [53])
Cancer patients Noncancer patients p value
All ECMO
ECMO mortality 58% (62/107)
Hospital mortality 65% (70/107)
Pulmonary ECMO
ECMO mortality 58% (50/86) 35% <0.0001
Hospital mortality 64% (55/86) 44% <0.0002
Cardiac ECMO
ECMO mortality 57% (8/14) 39% 0.17
Hospital mortality 71% (10/14) 55% 0.22
ECMO= extracorporeal membrane oxygenation.
aIncludes 86 pulmonary ECMO, 14 cardiac ECMO, and 7 ECMO for
cardiopulmonary resuscitation.
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ately. Administration of intravenous immunoglobulin
may be considered in children with severe sepsis
(weak recommendation), although a recent meta-
analysis does not recommend their use in current
practice in the adult population [46]. According to
international guidelines [47,48], hematopoietic growth
factors should be part of the treatment of febrile
neutropenia in patients at high risk of infectious
complications (expected prolonged (>10 days) or
profound (<0.1 × 109/L) neutropenia, uncontrolled
primary disease, pneumonia, hypotension, and multi-
organ dysfunction) [47] or in patients unresponsive to
antibiotics or with life-threatening complications [48].
Granulocyte transfusions are not recommended as a
routine treatment and should be reserved for special
situations [49].
Finally, extracorporeal blood purification therapies,
such as high-volume hemofiltration, hemoadsorption
with sorbents, such as polymyxin B, or plasmapheresis
have been proposed for adults with sepsis given their
immunomodulation potential associated with improve-
ment of different physiologic parameters [50,51]. How-
ever, important questions regarding these strategies
remain unanswered, and evidence of their usefulness in
pediatrics is absent. Large trials are required before
extracorporeal blood purification can be considered for
standard clinical practice [50,51].
Cancer and extracorporeal life support (ECLS)
Previously, many have argued that patients with cancer
should not receive ECLS [52]. Recently, Gow et al.
examined the Extracorporeal Life Support Organisation
data from 1992 to 2007 pertaining to patients with a
diagnosis of cancer and younger than age 21 years at the
time of ECLS (n = 107) [53]. Table 2 displays the mortal-
ity rates of these patients.
This study showed that the rate of infectious compli-
cations was not higher than that observed in children
without oncologic disease on ECLS (26% vs. 13–30%, re-
spectively [54,55]). However, cardiovascular and renal
complications (renal failure requiring replacement ther-
apy, arterial hypertension, cardiovascular failure requir-
ing inotropic support, and cardiorespiratory arrest) seem
to be more common in children with cancer. Based on
these data, it does not seem unreasonable to consider
ECLS in children with cancer who meet the necessary
criteria, including reversible pulmonary and/or heart
failure persisting despite maximal medical therapy [53].
In practice, most centers do not exclude children with
cancer from their ECLS programs as evidenced by a sur-
vey conducted in 118 centers belonging to the Extracor-
poreal Life Support Organisation. Seventy-eight percent
of the surveyed centers stated that cancer was not acontraindication for ECLS, although it was considered a
relative or absolute contraindication in 17% and 5% of
the centers, respectively [53]. Despite the inherent selec-
tion bias (all respondents practiced ECLS), this survey
demonstrates that ECLS may be considered as part of
the PICU treatment offered to children with cancer.Children with HSCT in the PICU
Since the first description of a bone marrow transplant
in a patient with leukemia in 1950 [56], indications and
modalities of this therapy have considerably evolved and
HSCT is now used for a wide array of malignant and
nonmalignant diseases. Despite many advances, HSCT is
still associated with a variety of complications that pose
serious threats to transplant recipients (graft versus host
disease (GVHD), severe sepsis, or organ dysfunction)
[21,57].Epidemiology
In 2008, approximately 2,400 children benefited from
HSCT in North America, with nearly 90% of transplants
related to cancer [58,59]. The proportion of transplanted
children admitted to the PICU varies between 10% and
20% [18,19,21-23,60,61] but a rate as high as 44% has
been reported [6]. Patients who received an allogeneic
transplant may be at greater risk of being admitted to
the PICU than those who received an autologous trans-
plant [21,22] although this is not a constant finding [8].
Patients transplanted late in the course of their disease
may be at greater risk of requiring intensive care than
those transplanted early [21,22]. Other risk factors for
PICU admission identified in allogenic HSCT patients
are the presence of GVHD and its severity [21,22], fluid
overload [8], and engraftment syndrome [22].
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The main reasons for admission are listed in Table 1. Re-
spiratory failure is the leading cause of admission [19,21-
23] followed by severe sepsis/septic shock [18,19,21,23].
Mortality and prognostic factors
The prognosis of children post-HSCT admitted to the
PICU was previously very grim, especially when invasive
ventilation was required. As shown in Table 3, the prog-
nosis for these children has improved during the past
decade; the PICU survival of ventilated children post-
HSCT increased from <20% to >50% [6-8,18,19,21-
23,25,60,61]. Survival at 6 months also seems to have
improved, although data are scarce for children trans-
planted after 2000.
However, this improvement is questioned by some
authors. In a retrospective analysis of a large American
database comparing children transplanted in 1997, 2000,
and 2003 (n = 5,699), Bratton et al. did not find any dif-
ference in mortality across the three study periods
amongst children post-HSCT who required invasive
ventilation (overall mortality 36%) [65]. In addition, a
meta-analysis conducted by Van Gestel et al. showed
that the decrease in the PICU mortality of children post-
HSCT between 1994 and 2000 was no longer statistically
significant after adjustment for the reduction in use of
mechanical ventilation observed during this period [66].Table 3 Survival of children post-HSCT admitted to the pedia




Nichols [62] 39 39 1978–1988 44
Keenan [63]a 121 121 1984–1996 -
Hayes [61] 39 44 1987–1997 27
Schneider [60] 28 28 1989–1998 50
Jacobe [18]b 40 57 1994–1998 56
Hagen [64]b 86 98 1990–1999 -
Lamas [25] 44 49 1991–2000 37
Diaz [22] 42 42 1993–2001 31
Leung Cheuk [19]b 19 24 1992 V2002 54
Tomaske [23] 23 26 1998–2001 42
Gonzalez-Vicent [21] 36 36 1998–2002 47
Kache [6]
All 81 NA 1992–2004 NA
1992–1999 48 NA 1992–1999 NA
2000–2004 33 NA 2000–2004 64
Van Gestel [7]* 35 38 1999–2007 -
Benoît [8] 19 19 2002–2004 68
NA= not available.
aExclusion of patients ventilated< 24 h; bincludes postoperative patients (Jacobe: 2Thus, it can be debated whether the overall improvement
in mortality is secondary to the optimization of manage-
ment and a less aggressive (or harmful) ventilatory strat-
egy or is merely due to having less severely ill patients
admitted to the PICU.
The prognosis of children post-HSCT admitted to the
PICU has to be put into perspective with their overall
prognosis, which has substantially improved. The rate of
complications that may lead to a PICU admission, such
as GVHD, sepsis, and respiratory failure, has decreased
as well as the hospital mortality (from 12% in 1997 to
6% in 2003 (p< 0.001)) [65]. In a recent study, Gooley
et al. [67] compared patients transplanted in 1993–1997
and in 2003–2007 and found a 41% decrease in mortal-
ity (p< 0.001) along with a significant reduction of al-
most all of the complications analyzed. Several factors
have been identified as contributing to these improved
outcomes: more judicious patient selection for trans-
plantation, less toxic conditioning regimens, improved
surveillance and early management of infectious compli-
cations, changes in the management of GVHD, new ven-
tilatory strategies, and changes in management of severe
sepsis [57,65,67].
Predictors of poor prognosis regularly reported in chil-
dren post-HSCT include the use of mechanical ventila-
tion [18,19,22,23,25,66] (especially in the presence of
lung disease [18,25,63,66]), the use of inotropic supporttric intensive care unit (PICU)
CU survival Survival≥ 6 months after PICU discharge
l Ventilated All Ventilated
% 9% NA NA
16% - 7%
% 15% 20.5% 12%
% 36% 21% 14%
% 42% 27% 13%
41% - 20%
% 23% 13.6% NA
% 21% 17% NA
% 15% 16% NA
% 15% 26% NA
% ND 44% NA
NA NA NA
NA 6% NA
% 59% NA NA
58% - 51%
% 50% NA NA
; Hagen: 5; Leung Cheuk: 4; Van Gestel: 1).
Demaret et al. Annals of Intensive Care 2012, 2:14 Page 6 of 11
http://www.annalsofintensivecare.com/content/2/1/14[21,25,60], multiorgan failure [7,18,19,63], and the need
for renal replacement therapy [18,23,60]. Other prognostic
factors, such as hyperbilirubinemia [18,64,68,69], GVHD
[6,18,19,25,60], and the type of transplant [18,21,23,25],
are more controversial. The underlying condition that
prompted the HSCT does not appear to affect prognosis
[23,25] nor does the time elapsed between transplant and
PICU admission [18,21]. All of these data must be inter-
preted with caution, because they result from single-
center retrospective studies, often of small sample size. In
the meta-analysis by van Gestel et al. [66], a decrease in
mortality over time was observed in the univariate
analysis, whereas mechanical ventilation was associated
with an increased risk of mortality. Only pulmonary dis-
ease remained significantly associated with mortality in
the multiple meta-regression analysis [66].
Composite scoring systems can be used to predict or
to describe the outcome of groups of patients admitted
to the intensive care [70]. These scores can be used for
quality assessment, economical assessment, monitoring
measurement, and research purposes. Commonly used
prognostic scores seem to be of limited value in popula-
tion of children post-HSCT, because they tend to
underestimate the mortality of these patients [18,23,61].
The Pediatric RISk of Mortality score (PRISM score)
evaluates the mortality risk based on data collected dur-
ing the first 24 hours in the PICU [71]. Some authors
have proposed to adapt this score by adding important
prognostic factors for children post-HSCT, thus creat-
ing the Oncological-PRISM score (O-PRISM) [60]. An
O-PRISM score ≥10 would suggest an increased risk of
mortality [21,23,72]. Such a score, which has not yet
been validated, could be used to better analyze cohorts
of children post-HSCT admitted to PICU and in the
evaluation of new treatment strategies.
Children post-HSCT and sepsis
Severe sepsis/septic shock is still a major cause of PICU
admission for children post-HSCT, although its inci-
dence has decreased over the years thanks to the devel-
opment of anti-infective strategies, the elaboration of
reduced-intensity regimens, and better monitoring of
subclinical infections [65].
The prognosis of severe sepsis is worse in children
post-HSCT than in nontransplanted children with can-
cer. Fiser et al. analyzed 446 separate PICU admissions
of 359 children with cancer with a diagnosis of septic
shock (defined as cardiovascular dysfunction requiring
fluid boluses or inotropic support in the presence of
fever and suspected or proven infection) [73]. PICU
mortality was 30% after HSCT versus 12% for other can-
cer patients (p< 0001). The logistic regression analysis
identified HSCT as one of the factors significantly asso-
ciated with mortality in children with cancer, requiringboth mechanical ventilation and inotropic support
(odds ratio 2.9; 95% confidence interval 1.1–7.4), to-
gether with PRISM score, fungal sepsis, and the need
for multiple inotropes. Six-month survival was 69%
among non-HSCT children versus 39% for children
post-HSCT (p< 0.01). Although these mortality rates
are substantial, they are not as bleak as previously feared
and should encourage the provision of intensive man-
agement of severe sepsis in children post-HSCT.
Renal replacement therapy in children post-HSCT
Children who have undergone HSCT are at high risk of
fluid overload due to voluntary intravenous hyperhydra-
tion, infusion of multiple antibiotics, veno-occlusive dis-
ease, and multiple transfusions of blood products. In
addition, the conditioning regimen may be associated
with renal toxicity and with some degree of systemic in-
flammatory response syndrome accompanied by a capil-
lary leak syndrome [74].
Preventing fluid overload is important in children
post-HSCT, because it has been identified as a risk factor
for PICU admission in a retrospective study [8]. More-
over, fluid overload worsens the prognosis of patients
with hypoxemic respiratory failure [75], a leading cause
of PICU admission for children post-HSCT.
The usefulness of renal replacement therapy (RRT)
has been questioned in children post-HSCT. Several
small retrospective studies have found a mortality rate
ranging from 75% to 100% in this population receiving
RRT [19,23,25]. However, Flores et al. recently reported
more encouraging results. The authors reviewed data of
51 children post-HSCT from an American prospective
registry of children receiving continuous RRT (CRRT)
[76]. They found a PICU mortality rate of 55%. Patients
requiring ventilatory support had a lower survival rate
than the nonventilated patients (35% vs. 71%, p< 0.05).
RRT could be beneficial through other mechanisms
than optimization of fluid balance. DiCarlo et al.
reported a series of ten children with cancer (including
six HSCT patients) who had developed ARDS and who
seemed to have benefited from early high-volume RRT
(continuous hemodiafiltration with a flow of 50 ml/min/
1.73 m2) initiated at or near the start of mechanical ven-
tilation, regardless of renal function [77]. Only four of
these children had renal dysfunction and fluid overload.
Nine of ten patients were extubated and eight survived
(follow-up until 18 months after discharge from the
PICU), suggesting that early initiation of CRRT in this
population could prevent inflammatory lung injuries in
addition to fluid overload. This concept is supported by
the finding of Rajasekaran et al. of an association be-
tween high C-reactive protein serum levels at the end of
CRRT and the risk of mortality (33 courses of CRRT
among 29 patients) [69].
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dren post-HSCT with ALI. Elbahlawan et al. published
recently a retrospective analysis of a pediatric HSCT
cohort admitted to the PICU and receiving CRRT during
a course of mechanical ventilation for ALI [74]. An im-
provement in oxygenation (PaO2/FiO2 ratio) was observed
24 hours and 48 hours after the beginning of CRRT. This
effect is likely to correlate with negative fluid balance. How-
ever, only five children survived to PICU discharge (17%).
Thus, it seems that RRT may be useful in children
post-HSCT, particularly in the presence of fluid over-
load. The concept of using high-dose RRT to promote
favorable clearance of inflammatory mediators is attract-
ive, especially because pro- and anti-inflammatory sys-
tems are probably dysregulated in these patients. Further
studies are required before this indication alone could
be retained in current practice.
Proposal of a decisional algorithm for critically ill children
with cancer
Discussions surrounding PICU admission of cancer chil-
dren may raise difficult and sensitive questions, especially
from an ethical standpoint. Establishing PICU admission
criteria for children with cancer may facilitate these dis-
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Figure 1 Decisional algorithm for critically ill children with cancer. PIC
transplantation; ECLS = extracorporeal life support. aUnless a decision regar
concept of PICU Trial is detailed in the text; cNew or progressive multiple o
Karnofsky score≥ 50% and a life expectancy ≥ 100 days.adapted from the adult literature [78], based on consensus
opinion of physicians caring for critically ill children with
cancer at our institutions. As a result, some items remain
subjective and are meant to be discussed case-by-case and
modified as needed according to clinical settings. This
highlights the paramount importance of constant dialogue
between hemato-oncologists and intensivists, as well as
with other health care professionals, the child, and his par-
ents. This dialogue is essential to ensure continuity of
high-quality care for these children with complex disease
and evolving medical status and to benefit from the ex-
perience of all those involved in their care.
PICU=pediatric intensive care unit; HSCT, hematopoietic
stem cell transplantation; ECLS = extracorporeal life
support. aUnless a decision regarding limitation of care
has been made before the intervention; bThe concept of
PICU Trial is detailed in the text; cNew or progressive
multiple organ dysfunction syndrome after days 3 to 5;
dMay be defined as a Karnofsky score ≥ 50% and a life
expectancy ≥ 100 days.
Similarly to the ICU admission policies recently pro-
posed by Azoulay et al. [78], we offer different PICU ad-
mission strategies based on the anticipated prognosis of
both the cancer and the condition leading to the PICU.
Patients at low risk for mortality should be treated like theMedical
complication 
Comfort care 
Preferably provided on the 
haemato-oncology ward 
ntermediate 
e treatment, HSCT) 
logical prognosis 
Poor
(relapsing disease with no hope of 
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admitted during the postoperative period and children in
the initial phase of the disease. However, as mentioned pre-
viously, this classification is an aid to clinical decisions and
should not be perceived as unchangeable. For example,
some children may have an intermediate or poor prognosis
even if they are in the initial phase of the disease, related to
the severity of the cancer. The decision to offer a “full sup-
port admission” rather than a “PICU trial” (see below) has
to result from a multidisciplinary discussion.
Like other authors [79], we consider that the concept
of an “ICU trial,” developed and studied in the adult
population [80], can be adapted to the pediatric popula-
tion. The ICU trial consists of unlimited ICU support
for a fixed time period, usually 3 to 5 days. The patient
course is reviewed a few days after ICU admission, be-
cause their status at this point is thought to be more
representative of their clinical condition and risk of
mortality than if such estimation was based on first-
ICU day values. This could help to identify patients
who remain severely ill despite maximal therapy, with
no improvement or with worsening condition, in whom
difficult decisions, such as limitation of treatment, may
be most appropriate [78,81]. In particular, the probabil-
ity of survival is low in patients with persistent or wor-
sening multiple organ failure after 48–72 hours [82-84],
as well as in transplanted patients with mechanical ven-
tilation exceeding 2 weeks [82]. As illustrated in the
proposed algorithm, the ICU trial is particularly pertin-
ent in critically ill patients with intermediate prognosis
of their oncologic disease. With respect to patients with
a poor hemato-oncologic prognosis (i.e., patients with
no hope of survival), we believe that it is important to
distinguish between two groups, according to the
anticipated duration and quality of life. Mid-term life
expectancy may be considered satisfactory in some
patients,for example those having a Lansky score [85]
(children aged 0–16 years) or a Karnofsky score [86]
(children older than age 16 years) ≥ 50% and a life
expectancy ≥ 100 days. The Lansky and the Karnofsky
scores are validated performance status scales that are
widely used to quantify the functional status of cancer
patients [85,86]. They are frequently used as criteria for
selecting patients for eligibility for phase I oncology
trials. These patients could benefit from PICU support,
after a discussion between the medical team and the
family, to establish a reasonable treatment plan adapted
to the patient’s needs. This plan usually excludes excep-
tional therapies (ECLS, RRT, high-frequency ventila-
tion) and needs to be reassessed on a daily basis.
On the other hand, patients with an anticipated poor
duration and/or quality of life will not benefit from
PICU support. The concept of palliative PICU admission
has been proposed [78] for patients in whom somespecific form of comfort care cannot be provided on the
ward; we believe that this situation is exceptional and
should be avoided.
Future observational studies are warranted to evaluate
this proposed algorithm for PICU admission in children
with cancer.
Conclusions
Children with cancer represent a population at risk for
complications that may lead to PICU admission. Their
prognosis has improved considerably during the past
20 years as a result of advances in hemato-oncology and
intensive care. Children post-HSCT also have benefited
from this progress, although they remain at a higher risk
of mortality.
Most children with cancer should be admitted to the
PICU if necessary and be considered eligible to receive
maximal therapy. If after a few days of intensive treat-
ment, there is absence of improvement, or progression
of multiple organ failure, the care plan should be
reviewed through adaptation of the level of support or
guidance toward palliative care. Discussions pertaining
to these important decisions should involve the intensi-
vists, the hemato-oncologists, the family, and the patient
when capable.
Large epidemiological studies in this population are
scarce. Prospective, multicenter studies would lead to a
better understanding of this population’s specificities
and optimize the admission strategies as well as the
management of these children in the PICU.
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